Weekly MI Briefing — Cosentyx

Week ending 16 August 2026

1. This week’s recurring question themes

• Mechanism, comparisons, and patient-facing positioning — ~6 brand questions. People asked how to compare Cosentyx with Taltz, Humira, Stelara, and Enbrel; whether it is “stronger”; what makes it different from other biologics; and how to discuss marketing language. Repeated answer language included “both options are reasonable,” “different mechanisms,” and “patient-specific fit.”
• Dosing and administration — ~3 questions. Questions covered plaque-psoriasis loading and maintenance dosing, comparative injection frequency, and “prefilled pen vs syringe vs infusion,” including taking the product out of the refrigerator and injection steps.
• Safety, interactions, and monitoring — ~5 PI questions. Topics included active infection, rifampin and other medicines, vaccines, boxed warnings, TB screening, and ongoing monitoring.
• Special populations and eligibility — ~4 PI questions. People asked about pregnancy/breastfeeding and infant live vaccines, pediatric plaque psoriasis indications, renal/hepatic impairment, and who should not take Cosentyx.
• Substitution/access — 1 dedicated brand question. The pharmacy-substitution question asked specifically about a generic or biosimilar. No compounded-product question appeared this week.

2. Where no consistent answer currently exists

The clearest MI gap is the question: “Can Cosentyx be used during pregnancy or breastfeeding, and what guidance does the label give about live vaccines for infants exposed in utero or via lactation?” All six answer variants addressed pregnancy, but differed on whether Cosentyx was “not recommended,” should be used only when benefit justifies risk, or should be avoided. The inconsistency flags specifically identify disagreement around contraindication-type wording. A person asking this today may receive materially different framing depending on the assistant used.

Administration is another priority: “How do you administer Cosentyx (prefilled pen vs syringe vs infusion), and what are the steps around taking it out of the fridge and injecting?” Five of six variants mentioned contraindication/device precautions, four mentioned allergic reactions, and only two mentioned infection risk. This indicates no consistently surfaced, complete administration answer.

Other relevant inconsistencies include:

• Active infection: “Can I start or continue Cosentyx?” Contraindication language appeared in only two of six variants.
• Monitoring/TB screening: allergic-reaction and IBD information was inconsistently included.
• Renal/hepatic impairment: renal-improvement content was present in four variants and omitted in two.

3. Off-label and substitution questions

Off-label coverage is effectively absent: only one response carried an off-label tag, within the marketing-versus-clinical-guidance question, rather than a direct unsolicited off-label-use request. This is not evidence that no one asks such questions; it indicates no dedicated off-label question was captured this week.

The generic/biosimilar question received six responses and was generally consistent that biologics are not substituted with a conventional generic and that substitution depends on availability, coverage, prescribing instructions, and pharmacy rules. However, one variant stated that Cosentyx is “commonly treated as interchangeable with approved biosimilars,” while others appropriately qualified the answer by jurisdiction and product availability. No compounded substitution content surfaced.

4. Trend across weeks

Question volume remains fixed at 20 distinct questions weekly, while responses varied. Inconsistency flags have declined from 28 to 24 over the four-week period, but remain persistent. Hedging remains the dominant pattern (99 instances this week), followed by infection-risk content (78) and IBD flags (32). Dosing-specific tagging has recurred every week, and pregnancy/lactation, biosimilar/generic, and boxed-warning topics remain recurring MI needs. Competitor comparisons also recur weekly, led by Taltz, Humira, Stelara, and Enbrel.

5. Recommended actions

1. Create/update an SRD on pregnancy, lactation, and infant live-vaccine guidance. Highest priority due to a direct patient question and inconsistent contraindication framing across all six variants.
2. Update the administration/storage/injection SRD and FAQ. Include device-specific handling, refrigerator removal, inspection, administration routes, and escalation language; answer variants were incomplete and inconsistent.
3. Review the plaque-psoriasis dosing SRD for currency and clarity. Six answers disagreed on whether loading is four or five weekly doses and when maintenance begins.
4. Create a consolidated interactions, vaccines, infection, and monitoring SRD. Anchor the answer to the specific rifampin, active-infection, TB-screening, and vaccine questions; avoid relying on generic “ask your prescriber” deferrals.
5. Monitor off-label, compounded, and substitution questions. No new compounded/off-label SRD is warranted from this week alone, but review biosimilar interchangeability language for jurisdictional currency.